Real-World Study of Cligabalin for the Treatment of Neurogenic Rosacea

NCT07606820 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-26

No results posted yet for this study

Summary

A Real-World Study of Cligabalin(HSK16149) for the Treatment of Neurogenic Rosacea

Conditions

  • Rosacea

Interventions

DRUG

HSK16149 20mg BID

different dose

DRUG

HSK16149 20mg qd

different dose

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2026-10-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606820 on ClinicalTrials.gov